Vista Pharmaceuticals Ltd
Incorporated in 1992, Vista Pharmaceuticals Ltd does manufacturing and selling of Pharmaceutical, medical and veterinary preparations. The company also sells products to its related companies engaged in the manufacture of formulations
- Market Cap ₹ 42.1 Cr.
- Current Price ₹ 10.8
- High / Low ₹ 16.6 / 9.10
- Stock P/E
- Book Value ₹ 12.4
- Dividend Yield 0.00 %
- ROCE -7.74 %
- ROE -11.0 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Stock is trading at 0.87 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 21.2%
- Company has a low return on equity of -9.93% over last 3 years.
- Company has high debtors of 515 days.
- Company's cost of borrowing seems high
- Promoter holding has decreased over last 3 years: -14.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7.47 | 8.30 | 13.75 | 15.38 | 24.18 | 28.92 | 31.07 | 22.76 | 1.27 | 0.39 | 1.00 | 10.12 | 9.98 | |
6.65 | 7.08 | 11.05 | 12.78 | 21.12 | 23.59 | 29.84 | 27.56 | 3.00 | 1.66 | 5.32 | 13.41 | 12.85 | |
Operating Profit | 0.82 | 1.22 | 2.70 | 2.60 | 3.06 | 5.33 | 1.23 | -4.80 | -1.73 | -1.27 | -4.32 | -3.29 | -2.87 |
OPM % | 10.98% | 14.70% | 19.64% | 16.91% | 12.66% | 18.43% | 3.96% | -21.09% | -136.22% | -325.64% | -432.00% | -32.51% | -28.76% |
0.01 | 0.03 | 0.01 | 0.02 | 0.06 | 0.40 | 2.95 | 3.75 | 0.20 | 0.17 | 0.40 | 0.07 | 0.30 | |
Interest | 0.01 | 0.00 | 0.41 | 0.77 | 0.88 | 1.57 | 1.67 | 1.54 | 1.55 | 0.90 | 1.34 | 1.24 | 1.03 |
Depreciation | 0.64 | 0.77 | 1.05 | 1.02 | 1.02 | 1.34 | 1.36 | 1.35 | 0.73 | 0.62 | 0.62 | 0.72 | 0.73 |
Profit before tax | 0.18 | 0.48 | 1.25 | 0.83 | 1.22 | 2.82 | 1.15 | -3.94 | -3.81 | -2.62 | -5.88 | -5.18 | -4.33 |
Tax % | 50.00% | 2.08% | -8.80% | 8.43% | -1.64% | 22.70% | 18.26% | -6.60% | -47.24% | -66.03% | -3.57% | -12.93% | |
0.08 | 0.47 | 1.36 | 0.77 | 1.25 | 2.19 | 0.94 | -3.68 | -2.01 | -0.89 | -5.66 | -4.51 | -3.06 | |
EPS in Rs | 0.01 | 0.06 | 0.11 | 0.06 | 0.47 | 0.75 | 0.31 | -1.21 | -0.55 | -0.24 | -1.54 | -1.16 | -0.79 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 2% |
5 Years: | -20% |
3 Years: | 100% |
TTM: | 40% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 38% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 7% |
3 Years: | 7% |
1 Year: | -23% |
Return on Equity | |
---|---|
10 Years: | -4% |
5 Years: | -10% |
3 Years: | -10% |
Last Year: | -11% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 15.00 | 15.00 | 5.00 | 5.00 | 5.31 | 5.83 | 6.07 | 6.07 | 7.36 | 7.36 | 7.51 | 9.43 | 12.31 |
Reserves | -6.37 | -5.91 | 5.44 | 6.21 | 11.29 | 26.03 | 29.73 | 23.57 | 25.49 | 28.09 | 29.20 | 31.03 | 35.92 |
0.00 | 0.00 | 4.04 | 7.88 | 11.33 | 11.06 | 11.17 | 15.47 | 10.71 | 12.55 | 9.96 | 7.96 | 6.85 | |
5.82 | 4.97 | 8.30 | 7.29 | 13.69 | 10.08 | 5.79 | 6.01 | 9.05 | 7.59 | 9.36 | 9.56 | 8.56 | |
Total Liabilities | 14.45 | 14.06 | 22.78 | 26.38 | 41.62 | 53.00 | 52.76 | 51.12 | 52.61 | 55.59 | 56.03 | 57.98 | 63.64 |
12.45 | 11.69 | 10.73 | 9.96 | 13.46 | 17.67 | 20.52 | 20.66 | 19.93 | 19.33 | 19.74 | 19.32 | 19.04 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 1.99 | 7.11 | 8.54 | 8.78 | 9.08 | 9.08 | 9.33 | 9.82 | 9.98 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.02 | 0.04 | 0.03 | 0.02 | 0.02 | 0.02 |
2.00 | 2.37 | 12.05 | 16.42 | 26.17 | 28.20 | 23.67 | 21.66 | 23.56 | 27.15 | 26.94 | 28.82 | 34.60 | |
Total Assets | 14.45 | 14.06 | 22.78 | 26.38 | 41.62 | 53.00 | 52.76 | 51.12 | 52.61 | 55.59 | 56.03 | 57.98 | 63.64 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.21 | -0.09 | -3.53 | -2.50 | 2.57 | -4.58 | 3.30 | 0.80 | -6.75 | -0.99 | -1.71 | -4.91 | |
-0.11 | 0.01 | -0.09 | -0.24 | -3.61 | -10.61 | -5.65 | -1.73 | -0.30 | -0.01 | -1.27 | -0.79 | |
-0.10 | 0.00 | 3.63 | 3.07 | 6.36 | 11.22 | 1.43 | 0.28 | 6.96 | 0.94 | 3.11 | 5.59 | |
Net Cash Flow | 0.00 | -0.08 | 0.00 | 0.34 | 5.32 | -3.98 | -0.92 | -0.64 | -0.09 | -0.07 | 0.13 | -0.11 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 0.00 | 45.30 | 299.70 | 231.15 | 136.01 | 137.06 | 98.09 | 164.86 | 623.66 | 9,789.49 | 4,106.25 | 515.04 |
Inventory Days | 106.33 | 51.61 | 10.20 | 96.66 | 184.54 | 249.51 | 161.60 | 147.59 | 4,840.00 | 9,203.92 | 990.53 | 278.78 |
Days Payable | 263.43 | 323.11 | 359.43 | 236.24 | 293.13 | 208.80 | 75.56 | 78.67 | 2,555.00 | 5,297.43 | 1,007.30 | 304.24 |
Cash Conversion Cycle | -157.11 | -226.21 | -49.53 | 91.57 | 27.41 | 177.77 | 184.14 | 233.77 | 2,908.66 | 13,695.97 | 4,089.48 | 489.58 |
Working Capital Days | -186.16 | -110.38 | 98.75 | 205.76 | 92.23 | 202.32 | 197.71 | 240.55 | 2,261.85 | 14,955.64 | 5,204.90 | 499.17 |
ROCE % | 2.20% | 5.42% | 14.09% | 9.53% | 8.93% | 12.39% | 6.27% | -5.21% | -5.10% | -3.76% | -9.59% | -7.74% |
Documents
Announcements
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
4h - Vista Pharmaceuticals confirms non-applicability as Large Corporate for FY 2024-25 per SEBI norms.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
4h - Vista Pharmaceuticals confirms it is not a Large Corporate; no outstanding borrowings as of March 31, 2024.
-
General Announcement - Financials Results
2d - Vista Pharmaceuticals reports audited FY23 net loss of Rs. 581.71 lakhs; audit unmodified opinion received.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
23 Apr - Vista Pharmaceuticals' FY24 secretarial compliance report details fines paid for delayed filings and governance lapses.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
21 Apr - Compliance certificate for securities dematerialization for quarter ended 31.03.2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
Company offers over-the-counter & prescription generic drug products consisting of tablets, capsules, and liquids covering various therapeutic categories. It formulates, registers, produce markets, and distributes pharmaceutical products. The company has its USFDA Approved Manufacturing Facility in India and its Marketing and Distribution Center in the USA.